The 24 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 114.50, with a high estimate of 151.14 and a low estimate of 78.00. The median estimate represents a +13.14% increase from the last price of 101.20.
The current consensus among 27 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.79
Reporting Date Nov 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.